Lasa Supergeneri (LASA)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At first glance, a price-to-book of 0.49 against a book value of ₹17.11 looks like a Graham cigar butt. But value investing is not simply buying low P/B; it is buying assets that earn an acceptable return. Lasa Supergeneri earns none. The latest quarter delivered only ₹2 crore in sales and a net loss of ₹3 crore. Sales have fallen by 93.35%. That is not a cyclical dip; that is franchise destruction. With ROE at -48.74% and ROCE at -1.00%, the company is destroying every rupee of equity it possesses. The Piotroski F-score of 2/9 reinforces this picture of distress. A P/E of 148.07 is worthless in this context—it comes from a tiny trailing profit while current operations are losing money. The only genuine positive is the low debt-to-equity of 0.13; the company is not at risk of imminent bankruptcy. Promoter holding of 53.65% does align incentives, but ownership concentration cannot compensate for absent customers and losses larger than revenue. At ₹8.36, the market cap is ₹40 crore against a book value of roughly ₹82 crore. That sounds tantalizing. But a book value built on pharma assets can shrink quickly when sales collapse; a business losing ₹3 crore on ₹2 crore quarterly revenue may have assets worth far less than stated. The 52-week range of ₹5.67 to ₹14.08 tells me this is a volatile, falling knife. Buffett would say it is far better to buy a wonderful company at a fair price than a fair company at a wonderful price. This is not a wonderful company. At best, it is an asset play for a patient scavenger, but only if operations stabilise and the assets prove real. Today, the evidence says wait.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer